Boya Pharmaceutical-B (02142.HK) appoints Gao Yifan as Co-Secretary of the Company.

Galaxy Securities October 24th, Hengbomei Pharmaceuticals-B (02142.HK) announced that on October 24th, 2024, the board of directors has approved the appointment of Ms. Gao Yifan as the joint company secretary of the company, effective from October 24th, 2024. The current company secretary, Mr. Lv Yingyi, will serve as another joint company secretary of the company.

Gelonghui FinanceOct 24 07:34 ET

Zhī Tōng Hong Kong Stocks Repurchase Statistics | October 11th

Hong Kong Stock Buyback Statistics | October 11th

Zhitong FinanceOct 10 21:10 ET

Pharmaron - B (02142) repurchased 8,000 shares on October 10th.

Pharmaceutical Company B (02142) announced that it will spend 0.0108 million Hong Kong dollars to repurchase... on October 10, 2024.

Zhitong FinanceOct 10 05:18 ET

The results of the Phase I clinical study of the innovative therapy Prusubaedonecept combined with anti-PD-1 antibody for the treatment of advanced melanoma and other solid tumors by Boao Pharmaceutical have been published.

On October 10, 2024, in Suzhou, China, Cambridge, Massachusetts, USA, and Rotterdam, the Netherlands / PRNewswire / - Hapo BioMed (stock code: 02142.HK), a global biomedical company focused on innovative antibody therapy discovery, development, and commercialization in the fields of oncology and immunology, announced today that the world's first fully humanized heavy chain antibody targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) PruSuzabamab (HBM4003) in combination with anti-PD-1 antibody Trepilumab for the treatment of advanced solid tumors (especially melanoma) Phase I clinical trial results have already been.

PR NewswireOct 9 22:57 ET

A Piece Of The Puzzle Missing From HBM Holdings Limited's (HKG:2142) 34% Share Price Climb

Simply Wall StOct 4 18:32 ET

Express News | Hbm Holdings Acquires Calcium Products

ReutersSep 25 10:15 ET